US Pharma MarketingEnergenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Energenesis has signed a development agreement with Taiwan Tanabe for its investigational topical drug ENERGI-F703DFU to treat DFUs.
Source: Pharmaceutical Technology